Related Experiment Video
Updated: Aug 8, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Improved glycemic control with the MiniMed 780G system in latent autoimmune diabetes and type 1 diabetes: a
Francesco De Vita1, Simona Zampetti1, Alessandro Latino1
1Department of Experimental Medicine, Sapienza University of Rome, Italy.
Aims:
To evaluate the effectiveness of the Medtronic MiniMed™ 780G Automated Hybrid Closed Loop System (AHCLS) in insulin-treated patients with latent autoimmune diabetes in adults (LADA).
Methods:
Continuous glucose monitoring (CGM) data and clinical records were collected from individuals with LADA using the MiniMed™ 780G. Participants were BMI-matched with individuals with LADA treated with multiple daily injections (MDI) + CGM and with people with type 1 diabetes (T1D) using either AHCLS or MDI + CGM. Multivariable regression models adjusted for age, sex, and diabetes duration were used to assess the effect of AHCLS on CGM metrics. Differences in treatment effect between LADA and T1D were evaluated through an interaction analysis.
Results:
AHCLS users showed higher time in range (TIR) than people on MDI (80 [71-87]% vs. 62 [50-75]%, p < 0.001) with no significant differences in the effect of AHCLS on TIR between people with LADA and T1D (p-interaction = 0.53). The percentages of patients meeting all CGM targets were 22.2% and 14.3% among people with LADA and T1D treated with MDI, and 54.4% and 77.8%, among those using AHCLS (p-value < 0.001; p-interaction = 0.39).
Conclusions:
MiniMed™ 780G markedly improves glycemic control in people with LADA, supporting AHCLS as an effective therapeutic strategy in this population.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Symptoms, Diagnosis, and Complications
Type I Diabetes I: Introduction
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis